A potential game-changing drug for use in the treatment of a common form of vision loss took a step closer to the FDA in October when Ophthotech (NASDAQ:OPHT) announced its second phase 3 trial of Fovista for wet age-related macular edema was now fully enrolled.
Investors cheered the news, sending shares up sharply last month, but can Ophthotech's shares continue to climb? In the following slideshow, I discuss Ophthotech's potential, including why a major deal with Novartis (NYSE:NVS) makes this company an intriguing investment for risk-tolerant investors.
Todd Campbell owns shares of Ophthotech. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.